Original Article

Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia


  • Abdullah Şumnu
  • Ali Erdem Dal

Received Date: 24.01.2020 Accepted Date: 10.06.2020 Med Bull Haseki 2020;58(4):338-343


We aimed to find the incidence of hypophoshatemia and to investigate predictive factors for the development of hypophospahtemia in patients with chronic kidney disease (CKD) treated with intravenous ferric carboxymaltose (FCM).


In our single center retrospective study, we included 43 adult patients who were given FCM therapy after nephrology clinic admission. Thirty-three non-dialysis CKD patients constituded the CKD group. Control group consisted of 11 patients with the diagnosis of iron deficiency anemia and normal renal function. Patients with missing data on serum phosphorus level before and after treatment were excluded.


The average age of CKD group was 68.8±10.2 years (69% female). The average serum creatinin level and and estimated glomerular filtration rate were 2.3±1.1 mg/dL and 29.7±17.6 mL/min/1.73m2, respectively. After the first week following FCM treatment, five of 11 patients in the control group (44.5%) and three of 32 patients in the CKD group (9.4%) developed hypophosphatemia (p=0.008). On linear regression analysis, it was found that baseline phosphorus level was the single predictor of hypophosphatemia (p=0.006).


Our study demonstrated that the incidence of hypophosphatemia associated with FCM treatment in CKD patients was compatible with the rates in the literature. Clinicians should be careful in FCM treatment especially in patients having low baseline phosphorus level.

Keywords: Chronic kidney disease, ferric carboxymaltose, hypophosphatemia

Full Text (Turkish)